Survival and disease reactivation after autologous stem cell transplantation for systemic sclerosis: a single-centre cohort

Systemic sclerosis (SSc) carries the highest disease-specific mortality among systemic rheumatic diseases; autologous haematopoietic stem cell transplantation (AHSCT) has emerged as 1 of the disease-modifying treatments for severe, rapidly progressive disease [1–3]. However, real-world data on predictors and patterns of disease reactivation after AHSCT remain limited, and consensus relapse criteria have only recently been proposed [4]. We aimed to characterise the incidence, timing, and clinical features of disease reactivation following AHSCT in SSc.